Description

A study by StrategyHelix indicates that the global clinical next-generation sequencing market is expected to increase by US$ 18.4 billion from 2022 to 2028, garnering a CAGR of 23.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for clinical next-generation sequencing. The global clinical next-generation sequencing market is segmented on the basis of component, disease class, disease category, test complexity, test purpose, and region. Based on component, the global clinical next-generation sequencing market is categorized into instrument, workflow solution (kits, services, etc.). On the basis of disease class, the global clinical next-generation sequencing market has been segmented into cancer, non-cancer. The non-cancer segment captured the largest share of the market in 2021. By disease category, the global clinical next-generation sequencing market has been segmented into cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation. According to the research, the oncology segment had the largest share in the global clinical next-generation sequencing market. Based upon test complexity, the global clinical next-generation sequencing market is categorized into hotspot, multi-gene, single gene, whole genome, whole/targeted exome. The multi-gene segment held the largest revenue share in 2021. On the basis of test purpose, the global clinical next-generation sequencing market has been segmented into diagnosis, monitoring, screening/early detection, therapy guidance. In terms of geography, the global clinical next-generation sequencing market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global clinical next-generation sequencing market is highly competitive. As of 2021, the major players in the global clinical next-generation sequencing market were ANGLE plc, Becton Dickinson and Company, BGI Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Techne Corporation, Burning Rock Biotech Limited, CareDx Inc., Danaher Corp., Epigenomics AG, Eurofins Scientific SE, EXACT Sciences Corporation, Fulgent Genetics Inc., GeneDx Inc., Guardant Health Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Qiagen N.V., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the clinical next-generation sequencing market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Component: instrument, workflow solution (kits, services, etc.)
Disease class: cancer, non-cancer
Disease category: cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation
Test complexity: hotspot, multi-gene, single gene, whole genome, whole/targeted exome
Test purpose: diagnosis, monitoring, screening/early detection, therapy guidance
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global clinical next-generation sequencing market
– Identify regional strategies and strategic priorities on the basis of local data
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Clinical next-generation sequencing market overview
Part 3. Market breakdown by component
– Instrument
– Workflow solution (kits, services, etc.)
Part 4. Market breakdown by disease class
– Cancer
– Non-cancer
Part 5. Market breakdown by disease category
– Cardiovascular
– Clinical microbiology and infectious diseases
– Mendelian disorders
– Metabolic/immune
– Neurological
– Oncology
– Reproductive health
– Transplantation
Part 6. Market breakdown by test complexity
– Hotspot
– Multi-gene
– Single gene
– Whole genome
– Whole/targeted exome
Part 7. Market breakdown by test purpose
– Diagnosis
– Monitoring
– Screening/early detection
– Therapy guidance
Part 8. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 9. Key companies
– ANGLE plc
– Becton, Dickinson and Company
– BGI Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Techne Corporation
– Burning Rock Biotech Limited
– CareDx, Inc.
– Danaher Corp.
– Epigenomics AG
– Eurofins Scientific SE
– EXACT Sciences Corporation
– Fulgent Genetics Inc.
– GeneDx Inc.
– Guardant Health, Inc.
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– Qiagen N.V.
– Quest Diagnostics Incorporated
– Roche Holding AG
– Thermo Fisher Scientific Inc.
About StrategyHelix
Disclaimer